Dividend stocks shine in times like these. They pay investors to wait until market conditions improve, and they often deliver solid returns even when the market flounders.

We asked three Motley Fool contributors to identify dividend stocks they would buy hand over fist in 2023. Here's why they chose AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Eli Lilly (NYSE: LLY).

Keith Speights (AbbVie): AbbVie's top-selling drug Humira faces significant competition from biosimilars in the U.S. market for the first time ever in 2023. That fact alone might scare off many investors. However, I think that AbbVie is actually a smart contrarian pick for several reasons.

Continue reading

Source Fool.com